Enterprise-Wide Cost Realignment Program now expected to deliver annual net cost savings of at least $4.0B, an incremental $500M versus mid-point of guidance range provided on August 1, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now
- M & A News: Pfizer (NYSE:PFE) to Seal $43B Seagen Deal, Analyst Remains Upbeat
- Pfizer’s acquisition of Seagen receives all regulatory approvals
- Pfizer says FDA, EMA accept Marstacimab regulatory submissions
- Pfizer presents results from Phase 3 BASIS clinical trial
